Blog

Preliminary results from a clinical trial testing focused ultrasound-induced blood-brain barrier (BBB) opening with drug delivery in three patients with Alzheimer’s disease have now been published in the prestigious New England Journal of Medicine (NEJM)

The 16th CTAD conference was held October 24–27 in Boston. Dr. Ali Rezai presented preliminary results from his clinical trial using focused ultrasound to open the blood-brain barrier after the delivery of aducanumab.

The Foundation’s chief technology officer, Rick Hamilton, shares how the Foundation team reviewed more than 130 papers to assess how artificial intelligent (AI) may improve clinical solutions in focused ultrasound. Learn about the three areas that emerged as fields of interest and what the Foundation is doing to assist as the focused ultrasound community embraces this burgeoning technology. This blog is also available as a vlog.

The technical, biomechanism, neuroscience, and clinical sessions addressed the use of focused ultrasound for neuromodulation.